Skip to content
Company Analysis

iRadimed Corporation IRMD

A comprehensive view of key metrics, scores, and financial health for iRadimed Corporation

Overview of IRADIMED CORPORATION

IRMD NGM
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Small Cap
IRADIMED CORPORATION (IRMD), is a Small Cap company, in the Medical Devices industry, last closed at $93.60, about 86.7% overvalued vs fair value, +60.9% 1Y return, placing in the top 10% of its sector.
Metrics P/E 55.6× Rev Growth 14.4% ROE 24.8% Gross Margin 76.8%
USD 93.60
-2.76%
(Delayed)
• Vol 90d: 34.0%
52-Week Range
Market Cap
$1.23B
Enterprise Value
$1.18B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Excellent
Health
Fair
Efficiency
Good
Valuation
Excellent
Growth
Good
Profitability
Excellent
Health
Fair
Efficiency
Good
Valuation
Excellent
Completeness: 82%
Confidence: 52%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.iradimed.com
HQ Orlando, FL
Fiscal year Dec 31

Next Events

Earnings Jul 30 Estimated

Fair Value Snapshot

Bear Base Bull
$11
$12
$14
Current: $93.60 -87% vs base

Engine Room Money Flow™

Small Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$83.8M
14.4%%
Gross Profit
$64.3M
14.2%%
Operating Income (GAAP)
$26.1M
19%%
EBITDA
$28.5M
25.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
76.7%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
1
Active Leaks
0/1
Improving
0
High Impact
0
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating iRadimed Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
82
/100
Strong
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Strong
93
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing IRMD's balance between Growth (32.0%), Profitability (44.5%), and Safety (23.5%). Growth 32% Safety 23% Profitability 44%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

67th percentile vs peers
67
Key Signals
Rev Growth YoY 14.4% 67p Revenue CAGR 3Y 16.3% 70p EPS CAGR 3Y 19.9% 74p TSR 1.26 93p EPS Growth YoY 16.2% 44p
Strengths
  • FCF Margin in top 20% of peers (22.9%, 96th percentile)
  • Gross Profit Margin in top 20% of peers (76.8%, 87th percentile)
  • Operating Margin in top 20% of peers (31.2%, 97th percentile)
  • ROIC in top 20% of peers (20.0%, 92th percentile)
Risks

No significant risks identified for this axis.

Profitability

93th percentile vs peers
93
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

49th percentile vs peers
49
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for iRadimed Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$12.42
- - -
-86.7% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000